{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:00:37Z","timestamp":1784833237628,"version":"3.55.0"},"reference-count":22,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["OoR2021 100008"],"award-info":[{"award-number":["OoR2021 100008"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Parosmia is a qualitative olfactory disorder characterised by a distorted perception of smell, often experienced as unpleasant or offensive. Although parosmia has multiple aetiologies, post-viral parosmia has become increasingly prevalent following the COVID-19 pandemic. In the UK, post-viral parosmia affects an estimated 637\u2009836 individuals and has a substantial negative impact on quality of life and mood. At present, there is no licensed or standardised treatment for this condition. Gabapentin, a gamma-aminobutyric acid analogue with neuromodulatory properties, has shown potential benefits at low doses in small, non-randomised studies; however, its efficacy requires further evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Use of Gabapentin in the Management of Post-Viral Parosmia: A Double-Blind, Randomised, Placebo-Controlled, Multi-Site Trial (COPANOS) is a phase III, double-blind, randomised, placebo-controlled trial comparing gabapentin with placebo in adults aged 18\u201365 years with post-viral parosmia persisting for \u22656 months and &lt;5 years. Participants will be randomised 1:1 to receive gabapentin, titrated to a maximum dose of 600\u2009mg daily or a matching placebo for 8 weeks. The primary outcome is the between-group difference in mean parosmia severity scores at the end of treatment (week 8), measured using the parosmia domain of the validated Smell-Qx questionnaire. Secondary outcomes include quality of life (Smell- Qx), olfactory function assessed using the Sniffin\u2019 Sticks test battery, safety and tolerability and objective parosmia severity measured with the Sniffin\u2019 Sticks Parosmia Test (SSParoT). The trial will recruit 90 participants across two UK sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Analysis<\/jats:title>\n                    <jats:p>The results will provide robust preliminary evidence on the efficacy and safety of low-dose gabapentin for managing post-viral parosmia and will inform the feasibility and design of targeted treatment guidelines. Defining effective treatment for post-viral parosmia is essential given the significant impact on patient well-being and the absence of current evidence-based interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial protocol has been reviewed and approved by Health Research Authority (HRA) and Health and Care Research Wales (HCRW): 25\/WA\/0298, 21\/10\/2025. Results will be analysed and published as soon as possible following trial completion. Findings will be summarised on the study webpage and shared with trial participants in plain English. Trial results will also be uploaded to relevant trial registries within 12 months of trial completion. The Rosetrees Trust will be acknowledged in all publications. Publications will follow International Committee of Medical Journal Editors authorship guidelines, and professional medical writers will not be used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN82171427\">ISRCTN82171427<\/jats:ext-link>\n                      , IRAS 1012783.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-119127","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:05:24Z","timestamp":1784829924000},"page":"e119127","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["COPANOS: use of gabapentin in the management of post-viral parosmia \u2013 a double-blind, randomised, placebo-controlled, multi-site trial \u2013 study protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"isrctn82171427","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-3414","authenticated-orcid":false,"given":"Umar","family":"Rehman","sequence":"first","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-938X","authenticated-orcid":false,"given":"Winston","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boniface","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie J","family":"Lund","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-3236","authenticated-orcid":false,"given":"Carl","family":"Philpott","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich, UK"},{"name":"The Norfolk Smell & Taste Clinic, Norfolk & Waveney ENT Service, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Lechner","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072311051616000_16.7.e119127.1","doi-asserted-by":"publisher","DOI":"10.1159\/000530211"},{"key":"2026072311051616000_16.7.e119127.2","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.483"},{"key":"2026072311051616000_16.7.e119127.3","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-024-01189-z","article-title":"Parosmia: Pathophysiology and Management","volume":"25","author":"Xu","year":"2025","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026072311051616000_16.7.e119127.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-06024-5"},{"key":"2026072311051616000_16.7.e119127.5","first-page":"93","article-title":"The burden of olfactory dysfunction during the COVID-19 pandemic in the United Kingdom","volume":"61","author":"Lechner","year":"2023","journal-title":"Rhinology"},{"key":"2026072311051616000_16.7.e119127.6","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22929"},{"key":"2026072311051616000_16.7.e119127.7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/alr.23117","article-title":"Gabapentin improves parosmia after COVID-19 infection","volume":"13","author":"Garcia","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"2026072311051616000_16.7.e119127.8","doi-asserted-by":"crossref","DOI":"10.1093\/chemse\/bjag001","article-title":"The APOLLO trial: a proof-of-concept study for vitamin A nasal drops in COVID-19-related postinfectious olfactory dysfunction","volume":"51","author":"Yeap","year":"2026","journal-title":"Chem Senses"},{"key":"2026072311051616000_16.7.e119127.9","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082189","article-title":"Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies","volume":"11","author":"Capra","year":"2023","journal-title":"Biomedicines"},{"key":"2026072311051616000_16.7.e119127.10","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041109","article-title":"Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial","volume":"11","author":"Di Stadio","year":"2023","journal-title":"Biomedicines"},{"key":"2026072311051616000_16.7.e119127.11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamaoto.2023.2958","article-title":"Efficacy of Gabapentin For Post\u2013COVID-19 Olfactory Dysfunction","volume":"149","author":"Mahadev","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026072311051616000_16.7.e119127.12","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-200411000-00001"},{"key":"2026072311051616000_16.7.e119127.13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164641","article-title":"Drug-Associated Parosmia: New Perspectives from the WHO Safety Database","volume":"11","author":"Merino","year":"2022","journal-title":"J Clin Med"},{"key":"2026072311051616000_16.7.e119127.14","unstructured":"Pregabalin side effects: common, severe, long term. Drugs.Com. Available: https:\/\/www.drugs.com\/sfx\/pregabalin-side-effects.html [Accessed 9 Feb 2026]."},{"key":"2026072311051616000_16.7.e119127.15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/j.pain.0000000000000554","article-title":"A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component","volume":"157","author":"Atkinson","year":"2016","journal-title":"Pain"},{"key":"2026072311051616000_16.7.e119127.16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/alr.22140","article-title":"Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss","volume":"8","author":"Nguyen","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"2026072311051616000_16.7.e119127.17","unstructured":"Gabapentin | Drugs | BNF content published by NICE. Available: https:\/\/bnf.nice.org.uk\/drugs\/gabapentin\/ [Accessed 9 Feb 2026]."},{"key":"2026072311051616000_16.7.e119127.18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2026072311051616000_16.7.e119127.19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/alr.23604","article-title":"The Development and Validation of the Smell-Qx Questionnaire, Based on a Systematic Review of the Literature and the COMET Initiative on the Development of Core Outcome Sets for Clinical Trials in Olfactory Disorders","volume":"15","author":"Lechner","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"2026072311051616000_16.7.e119127.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2012.02431.x"},{"key":"2026072311051616000_16.7.e119127.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74967-0","article-title":"Assessment of odor hedonic perception: the Sniffin\u2019 sticks parosmia test (SSParoT)","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"2026072311051616000_16.7.e119127.22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00405-022-07574-6","article-title":"Assessment of postviral qualitative olfactory dysfunction using the short SSParoT in patients with and without parosmia","volume":"280","author":"Sekine","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-119127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:05:27Z","timestamp":1784829927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-119127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-119127"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-119127","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}